Metastatic pancreatic cancer: old drugs, new paradigms.
Thierry Conroy, Céline Gavoille, Antoine Adenis
https://pubmed.ncbi.nlm.nih.gov/21505335/Actively Recruiting
Led by University Hospital, Montpellier · Updated on 2026-06-22
63
Participants Needed
1
Research Sites
119 weeks
Total Duration
Researchers are investigating pancreatic adenocarcinoma and metastatic breast cancer, focusing on circulating tumor cells CTCs that detach from primary tumors and spread to other organs. These CTCs, when expressing the AXL protein, are linked to tumor growth, survival, and drug resistance. The study aims to compare two methods for detecting AXL-expressing CTCs using liquid biopsy, a non-invasive blood test, to improve understanding of tumor progression and treatment monitoring. Participants will have their blood tested using two techniques the FDA-approved CellSearch system and the innovative EPIDROP method. Both methods isolate and analyze CTCs expressing AXL to assess concordance and accuracy. The study also explores immune system markers and the potential to create a biobank of plasma samples. The goal is to better characterize CTCs and their role in pancreatic cancer prognosis and therapy. Throughout the trial, participants will undergo blood sampling and immune analysis at inclusion. Researchers will measure the concordance of CTC-AXL detection between methods and evaluate overall survival and progression-free survival over 36 months. Additional assessments include immune cell evaluations and PD-L1 expression on CTCs. This detailed monitoring helps understand the relationship between CTCs, immune response, and clinical outcomes in metastatic pancreatic cancer.
CONDITIONS
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)
T
Thomas Bardol, MD
S
Sarah Girot
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Montpellier
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Thierry Conroy, Céline Gavoille, Antoine Adenis
https://pubmed.ncbi.nlm.nih.gov/21505335/Sheng Zhang, Xiang Shang Xu, Jie Xi Yang...
https://pubmed.ncbi.nlm.nih.gov/29416351/Klaus Pantel, Catherine Alix-Panabières
https://pubmed.ncbi.nlm.nih.gov/20667783/Catherine Alix-Panabières, Klaus Pantel
https://pubmed.ncbi.nlm.nih.gov/33811121/Laura Cerchia, Carla L Esposito, Simona Camorani...
https://pubmed.ncbi.nlm.nih.gov/22910292/Jan-Bart M Koorstra, Collins A Karikari, Georg Feldmann...
https://pubmed.ncbi.nlm.nih.gov/19252414/Klaus Pantel, Catherine Alix-Panabières
https://pubmed.ncbi.nlm.nih.gov/28397823/Thierry Conroy, Pascal Hammel, Mohamed Hebbar...
https://pubmed.ncbi.nlm.nih.gov/30575490/K-Y Tai, Y-S Shieh, C-S Lee...
https://pubmed.ncbi.nlm.nih.gov/18345028/Catherine Alix-Panabières
https://pubmed.ncbi.nlm.nih.gov/32214259/University Hospital, Montpellier
Lead Sponsor